More Articles Back to Article
- Decentralized Clinical Trials in APAC Here to Stay
- DIA China 2021: Preparing for Unknown Risks in Exploratory Clinical Trials: Guideline from China CDE
- DIA China 2021: Global Pharmaceutical Regulation Evolving and Modernizing to Protect Public Health
- DIA China 2021: China GVP: Lifecycle Pharmacovigilance and Patient Safety
- Digital Endpoints Must Meet Patient Needs: Multi-Stakeholder Effort Required – One Size Does Not Fit All
Decentralized Clinical Trials in APAC Here to Stay
The face of clinical trials has been changing rapidly, and while decentralized clinical trials have been explored by the industry for many years, the COVID-19 pandemic has exponentially accelerated the shift towards such trials with increased urgency.
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!